Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas

Recent Developments in Cancer Vaccines

(2011) K. Palucka et al.   JOURNAL OF IMMUNOLOGY

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Lapatinib in breast cancer: clinical experiences and future perspectives

(2010) M. Giampaglia et al.   CANCER TREATMENT REVIEWS

Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma

(2010) M.-d.-M. Inda et al.   GENES & DEVELOPMENT

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies

(2010) Monika Witusik-Perkowska et al.   JOURNAL OF NEURO-ONCOLOGY

Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology

(2010) K. R. Porter et al.   NEURO-ONCOLOGY

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model

(2009) L. Zhang et al.   BLOOD

EGFRvIII-Targeted Vaccination Therapy of Malignant Glioma

(2009) Bryan D. Choi et al.   BRAIN PATHOLOGY

EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma

(2009) B. Mukherjee et al.   CANCER RESEARCH

A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining

(2009) Rafal Wierzbicki et al.   INVESTIGATIONAL NEW DRUGS

Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells

(2009) Angel Ayuso-Sacido et al.   JOURNAL OF NEURO-ONCOLOGY

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

(2009) J. H. Sampson et al.   MOLECULAR CANCER THERAPEUTICS

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

(2009) A F Gazdar   ONCOGENE

EGF receptor variant III as a target antigen for tumor immunotherapy

(2008) Gordon Li et al.   Expert Review of Vaccines

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

(2008) Mark E. Dudley et al.   JOURNAL OF CLINICAL ONCOLOGY

Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines

(2008) Robert J. Schmittling et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

(2008) J. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

(2008) F. S. Hodi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE